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Introduction: Cancer of the cervix rank the second most common cause of cancer related deaths among women
in Sub-Saharan Africa. It is estimated that 529, 409 new cases are diagnosed annually with a mortality rate
approaching 274,883 per year. Cervical Intraepithelial Neoplasia (CIN) precedes almost all cervical cancers. The
incidence rate of CIN among HIV infected women is five times higher as compared to the rate in HIV negative
women. The screening for cervical dysplasia and an appropriate management in women with CIN are effective
methods for preventing cervical cancer. This study was done to determine the prevalence and predictors of CIN
among a HIV infected women attending Care and Treatment centre (CTC) at Bugando Medical Centre (BMC).
Methods: A cross sectional survey was undertaken among HIV infected women aged 18 years and above
attending at BMC CTC clinic between February and March 2013. Visual Inspection with Acetic acid (VIA) was used
as the screening method for detection of CIN. Socio-demographic, reproductive and clinical information was
obtained from participants and the blood was collected for CD4 lymphocyte count. Cervical punch biopsy for
histological examination was performed for those who had VIA positive test. Data were entered and analyzed using
STATA Version 12.0 soft ware.
Results: A total number of 95 (26.8%) participants had positive VIA test among three hundred and fifty-five (355)
HIV infected women. Histology results showed; 4(4.2%) were normal, 26 (27.4%) had an inflammatory lesion, 58
(61.1%) had CIN and 7(7.3%) had invasive cervical cancer. CIN was found to be associated with a history of multiple
sexual partners (P<0.001), a history of genital warts (P<0.001), and a history of STI (P = 0.010).
Conclusion: The Cervical Intraepithelial Neoplasia is a problem among HIV infected women. A history of multiple
sexual partners, a history of genital warts, a history STI and a low baseline CD4 T lymphocyte were significant
predictors for CIN. Screening for Cervical Intraepithelial Neoplasia is recommended for all women with HIV.
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Cervical cancer and HIV/AIDS are major public health
problems. Worldwide, cancer of the cervix is the second
most common cancer among women, with 529,409 new
cases and 274,883 deaths annually. The developing
countries constitute 86% of the newly diagnosed cases
and 88% of the deaths [1]. The age-adjusted incidence
rate of cervical cancer in Tanzania is estimated to be
50.9 cases per 100,000 world standard women popula-
tion, with an age adjusted mortality rate of 37.5 per
100,000 [2]. Cervical Intraepithelial Neoplasia (CIN) pre-
cedes almost all cervical cancers. A study undertaken in
Conakry Guinea, reported that the incidence rate of CIN
among HIV-infected women was 4-5 times higher com-
pared to those with no HIV infection [3]. In an attempt
to reduce the cervical cancer burden, the Ocean Road
Cancer Institute in Dar-Es-Salaam introduced a cervical
cancer screening programme using Visual Inspection
with acetic acid (VIA) in different satellite clinics
throughout the country [4]. Despite this, there has been
a rise in the incidence of cervical cancer in Tanzania [5].
In developing countries, the prevalence of CIN among
HIV infected women is reported to be very high [6]. A
study in Lusaka Zambia evaluated 150 women, using the
Papanicolau smear test; more than 93% had CIN with a
median CD4 count of 165cells/mm3 [6].
The high prevalence of cervical cancer in patients with
advanced HIV/AIDS infection led to its inclusion among
AIDS defining conditions [5]. Currently, it is recognized
that HIV infected women have a higher prevalence of
Human Papilloma Virus (HPV) and the risk of infection
increases with the extent of immunosuppression [7]. A
higher prevalence of persistent infections with multiple
high risk-HPV strains contributes to a greater risk of
precancerous lesions [7]. The natural history of cervical
cancer follows a prolonged period of a pre-malignant
disease stage, commonly described as CIN which can
take as up to 10 years before the progression to invasive
cancer [8]. This shows that there is sufficient time for
the women to be screened for cervical cancer and re-
ceive the appropriate treatment [7]. Studies have re-
ported that, among HIV infected women, the risk of
developing cervical cancer is 10 years earlier than in the
general population, with a high rate of progression to an
advanced disease with a poor prognosis [9]. Other risk
factors include: age, lifetime number of sexual partners
(more than four), early sexual debut, high parity, im-
munosuppression, smoking and oral contraceptive use
for more than five years [9,10].
The Papanicolau smear test is the most widely used
cervical cancer screening test, having a higher sensitivity
and specificity compared to other tests [11]. However,
currently, Visual Inspection with Acetic acid has been
advocated as an alternative screening method to thePapanicolau smear in developing countries and this test
has high sensitivity and specificity [12]. The Papanicolau
smear is difficult to implement in resource limited set-
tings due to inadequate laboratories, and lack of expert
specialists. It requests a greater number of visits than
the VIA and therefore increase the cost. VIA provides an
effective alternative method with fewer logistical and
technical constraints [12]. A study conducted in 1999 in
Zimbabwe showed that VIA was a valuable tool for the
detection of pre-cancerous lesions with a sensitivity of
76.7% compared to 44.3% for cytology. However, the
specificity of VIA was lower (64.1%) than that of cy-
tology (90.6%). The authors also found that the cervical
abnormalities detected by VIA, 75% concurred with
those detected by biopsy [13].
Although numerous studies have documented the as-
sociation between HIV infection and the presence of
CIN, very few have assessed the associated risk factors
specific to HIV infected women. The prevalence of CIN
in Tanzania is quite variable, ranging from 2.9% to 38%
[14,15]. A study conducted among attendees at the
Makongoro Clinic in Mwanza Region found the preva-
lence of Squamous Intraepithelial Lesion (SIL) to be 7%;
HPV was 34%, whereby 83% of HPV was of high risk
oncogenic strains [16]. The high prevalence of HPV and
CIN among a low risk population is a matter of great
concern, which emphasizes the need to conduct a study
on the prevalence and predictors of CIN among a high
risk population.
Previous studies have recommended the need for cer-
vical cancer screening among HIV infected women. How-
ever none have suggested which screening test should be
used, Papanicolau smear or VIA, for the detection of pre-
malignant cervical lesions, especially in a low resource
setting [6,14,17]. This is partly due to the lack of docu-
mentation concerning screening tests and protocols for
HIV infected women. The aim of the present study was to
determine the number of women with biopsy proven CIN
and the predictors of CIN in HIV infected women using
VIA as an alternative screening method to the Papanico-
lau smear in a resource limited setting.
Methods
A cross sectional study was conducted between February
and March 2013 at the HIV Care and Treatment Centre
at Bugando Medical Centre, which receives an average
of 80 visiting HIV infected women per day [18]. The
clinic attends to patients who are on anti-retroviral
drugs and to those who have not started antiretroviral
therapy. The exclusion criteria for participation in the
study were: allergy to acetic acid, prior total hysterec-
tomy, wedge resection of the cervix, previous abnormal
Papanicolau smear, a history of cervical cancer and
pregnancy.
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ticipant each day from CTC register book. Thereafter
every third person was included systematically in the
study, until the required sample was reached. In case of
refusal or not meeting the inclusion criteria, the next
person was selected.
Data was collected using a structured pre-tested ques-
tionnaire. The interview was conducted in the language
in which the interviewee was proficient (Swahili, English,
indigenous language) with the help of an interpreter
when necessary. The gathered information included
socio-demographic characteristics, gynecological history,
obstetric history and whether she had previously been
screened for cervical cancer.
Participants with a proven HIV positive diagnosis had
a CD4 lymphocyte count check using a blood sample
collected through venopuncture.
A pelvic/Speculum examination was performed for the
recruited participants in which inspection and visualization
under an adequate light source was conducted. A solution
of freshly diluted 5% acetic acid was then painted to the
mucosa of the cervix using a cotton swab tipped applicator.
The detection of any distinct Acetowhite areas within the
transformation zone was considered to be positive after
4 minutes of waiting. Punch biopsies to determine the ac-
curacy of the cervical evaluation were performed for all
participants who were VIA positive. The samples were
fixed in 10% formalin, labeled with the patients study num-
ber and sent to the laboratory for histo-pathological exam-
ination. Those with abnormal histological results were
referred for follow up and management at the gynecology/
oncology clinic. Cryotherapy was performed on the same
setting for lesions about 5 cm width or above. For clinical
suspicious cervical cancerous lesions, patients were referred
to a gynaecologist for appropriate care and management.
Data were double-entered in Epidata 3.1 (Epidata
Association Odense Denmark) and cleaned and analyzed
using STATA 12.0 (College Station, Texas, USA). De-
scriptive statistics were used to demonstrate the demo-
graphic data and prevalence of cervical lesions among
HIV infected women using VIA. Univariate and multi-
variate logistic regression were carried out to analyze
factors/predictors of cervical intraepithelial neoplasia.
Estimation of odds ratios and their 95% confidence
interval, comparing the odds of each outcome between
predictor groups was also done. An association was con-
sidered significant when the p-value was less than 0.05.
Results
A total number of 1853 HIV infected women attended
at the HIV clinic of BMC between February and March
2013. Three hundred and fifty five (355) HIV infected
women were eligible for the study and were screened for
the cancer of cervix. The median age of the participantswas 38 years (range 18-63 years). The majority of partici-
pants were from urban area (81%) and a third was mar-
ried women (33%). The majority of the respondents 225
(71.8%) had primary education.
Among the women with malignant and pre-malignant
cervical lesions, 44 (75%) had a sexual debut before the
age of 18 years and a median number of sexual partners
reported in this study was four (range 1-8). A history of
genital warts and a history of STI were reported among
53(91.4%) and 56 (97%) of the women with CIN respect-
ively. None of the participants had ever been screened
for cervical cancer previously. [See Tables 1 and 2].
Ninety-five (95) HIV infected women tested positive
after the VIA test. This group was further subjected to a
histo-pathological examination and results were as fol-
lows: 4 (4.2%) were normal, 26 (27.4%) had an inflamma-
tory lesion, 58(61.1%) had CIN, whereby 31 (53.4%) had
CIN1 and 27(46.6%) had CIN2/3. Seven women (7.37%)
had invasive cervical cancer.
An age at first sexual intercourse of less than 18 years
was associated with CIN (OR 0.14; 95%CI 0.07-0.27,
P<0.001). A number of life time sexual partners of more
than 1 increased the likelihood of having CIN (OR 1;
95% CI 0.06-0.21, P<0.001) and a history of genital warts
was significantly associated with CIN (OR 27.33; 95%CI
10.6-70.8 P<0.001). CIN was more common in partici-
pants with a previous history of STI (OR 13; 95%CI 3.1-
54.3, P<0.001). [See Table 3 and 4]
Exposure to cigarette smoking was more likely to in-
crease the risk of CIN than non-exposure (OR 1.95, 95%
CI 1.01-3.78, P= 0.04). The prevalence of CIN was
higher among women with a baseline CD4 T lympho-
cytes count of less than 200 cells/mm3 (OR 1; 95% CI 0,
25-0.80, P=0.007).
There was no significant association between CIN and
age, marital status, contraceptive use, parity or current
CD4 count. The use of HAART and the number of years
since HIV diagnosis were not associated with CIN [See
Table 4].
The predictors which had a significant association with
CIN in Univariate analysis were subjected to multivariate
analysis. The predictors for CIN among HIV infected
women were the number of life time sexual partners
(Adjusted OR 4.06; 95% CI 1.86-8.88, P<0.001), a history
of genital warts (Adjusted OR 16.6; 95% CI5.91- 47.0,
P<0.001), a history of STI (Adjusted OR 7.39; 95% CI
1.67-33.66, P=0.010) and a baseline CD4 lymphocytes
count of less than 200cells/mm3 (Adjusted OR 2.71; 95%
CI 01.24-5.90, P=0.012) [ See Table 5].
Discussion
In this study 95 out of 355 (26.8%) HIV infected women
had cervical lesions (VIA positive) that warranted histo-
logical evaluation. This finding was lower than that
Table 1 Socio demographic, clinical and reproductive







n % n % n %
Age
18-25 years 20 (6.7) 1 (1.7) 21 (5.9)
26-35 years 95 (32.0) 26 (44.8) 121 (34.1)
36-49 years 148 (49.8) 24 (41.4) 172 (48.4)
50+ years 34 (11.5) 7 (12.1) 41 (11.6)
Residence
Urban 244 (82.2) 44 (75.9) 288 (81.1)
Rural 53 (17.8) 14 (24.1) 67 (18.9)
Marital status
Single 32 (10.8) 5 (8.60) 37 (10.4)
Married 107 (36.0) 12 (20.7) 119 (33.5)
Divorced 74 (24.9) 20 (34.5) 94 (26.5)
Separated 4 (1.4) 2 (3.50) 6 (1.7)
Widowed 80 (26.9) 19 (32.8) 99 (27.9)
Education
None 50 (16.8) 5 (8.6) 55 (15.5)
Primary 208 (70.0) 47 (81.0) 255 (71.8)
Secondary 32 (10.8) 4 (6.9) 36 (10.1)
College or above 7 (2.4) 2 (3.5) 9 (2.5)
Sexual Debut
Less than 18 yrs 90 (30.3) 44 (75.9) 134 (37.8)
18 years and above 207 (69.7) 14 (24.1) 221 (62.2)
Lifetime sexual partners
One partner 16 (5.4) 0 (0.0) 5 (4.5)
2-5 partners 235 (79.1) 21 (36.2) 256 (72.1)
5+ partners 46 (15.5) 37 (63.8) 83 (23.4)
Condom use
Never 134 (45.1) 33 (56.9) 167 (47.0)
Sometimes 133 (44.8) 21 (36.20) 154 (43.4)
Always 30 (10.1) 4 (6.9) 34 (9.6)
History of genital warts
Yes 83 (27.9) 53 (91.4) 136 (38.3)
No 214 (72.1) 5 (8.6) 219 (61.7)
History of STI
Yes 203 (68.4) 56 (96.6) 259 (73.0)
No 94 (31.6) 2 (3.4) 96 (27.0)
Table 2 Socio-demographic, clinical and reproductive







n % n % n %
Exposure to cigarette
smoke
Yes 107 (36.0) 13 (22.4) 120 (33.8)
No 190 (64.0) 45 (77.6) 235 (66.2)
Ever used
contraceptives
Yes 108 (36.4) 21 (36.2) 129 (36.3)
No 189 (63.6) 37 (63.8) 226 (63.7)
Parity
Nullipara 19 (6.4) 5 (8.6) 24 (6.8)
1-2 120 (40.4) 15 (25.9) 135 (38.0)
3-5 116 (39.1) 33 (56.9) 149 (42.0)
5+ 42 (14.1) 5 (8.6) 47 (13.2)
Baseline CD4 Count
Less than 200 cells/
mm3
116 (39.1) 34 (58.6) 150 (42.3)
200 cells/mm3 or more 181 (60.9) 24 (41.40 205 (57.7)
Current CD count
Less than 200 cells/
mm3
25 (8.4) 7 (12.1) 32 (9.0)
200 cells/mm3 or more 272 (91.6) 51 (87.9) 323 (91.0)
HIV drugs
Yes 229 (77.1) 49 (84.5) 278 (78.3)
No 68 (22.9) 9 (15.5) 77 (21.7)
Years living with HIV
6 months – 1 year 57 (19.2) 10 (17.2) 67 (18.9)
1 year-2 years 56 (18.9) 10 (17.2) 66 (18.6)
2 years and above 184 (61.9) 28 (65.5) 222 (62.5)
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Salaam whereby 42.2% were Aceto white positive [19]. This
difference can be explained by the a relatively lower median
CD4 count of their population which was 351cells/
mm3compared to this study where the median CD4 count
was 450cells/mm3. The lower the CD4 count and advancedstage of HIV could be responsible for a higher prevalence
of cervical lesions seen in their study [19]. In the present
study, the prevalence of CIN proven by biopsy was 16.0%.
Our findings are consistent with a work reported by Miotti
et al among 268 postpartum women of Malawi, whereby
the prevalence of CIN was 15% [20]. Although the preva-
lence of CIN in this population appears to be low, it is
within the range described in similar publications in Africa
[6,21]. A Botswana study, among HIV infected women
using VIA showed a prevalence of 11%, and another study
among HIV infected women in Senegal showed a preva-
lence of 10% [22,23]. In Africa, a high prevalence of CIN
(76%) among HIV infected women has been observed in
Lusaka Zambia [6]. The probable explanation could be a
HIV induced immune-suppression as the median CD4
count was low (165 cells/mm3) compared to our study in
which the median baseline CD4 count and current CD4











N % N %
Age
18-25 years 20 (6.7) 1 (1.7) 1
26-35 years 95 (32.0) 26 (44.8) 5.47 [0.70-42.71] 0.105
36-49 years 148 (49.8) 24 (41.4) 3.24 [0.42-25.30] 0.262
50+ years 34 (11.5) 7 (12.1) 4.12 [0.47-35.95] 0.200
Marital status
Single 32 (10.8) 5 (8.6) 1
Married 107 (36.0) 12 (20.7) 0.72 [0.23-2.19] 0.560
Divorced 74 (24.9) 20 (34.5) 1.73 [0.60-5.01] 0.313
Separated 4 (1.4) 2 (3.5) 3.20 [0.46-22.30] 0.240
Widowed 80 (26.9) 19 (32.8) 1.52 [0.52-4.42] 0.442




90 (30.3) 44 (75.9) 1
18 years and
above
207 (69.7) 14 (24.1) 0.14 [0.07-0.27] <0.001
No. of live time
sexual partners
One partner 16 (5.4) 0 (0.0)
2-5 partners 235 (79.1) 21 (36.2) 0.11 [0.06-0.21] <0.001
5+ partners 46 (15.5) 37 (63.8) 1
History of
genital warts
No 214 (72.1) 5 (8.6) 1
Yes 83 (27.9) 53 (91.4) 27.3 [10.6-70.8] <0.001
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Other studies in Tanzania reported a higher CIN preva-
lence of 32% and 38% [15,17]. In those studies, conven-
tional cytology was used as a screening method, and biopsy
was not done.
The prevalence of CIN in the present study was higher
than that found in a study by Mayaud et al among ante-
natal clinic attendees at the Makongoro clinic Mwanza
which was 7%. The difference can be explained by the fact
that Mayaud’s study involved the general population at the
clinic while the present study involved newly diagnosed
HIV participants and those who were in follow up for HIV
status in tertiary hospital [16]. VIA was offered to 355
women and 26.8% of these women had VIA positive re-
sults. This was similar to a study by De Vuyst et al among
653 women attending Nairobi family planning clinic,
whereby 27% women had VIA positive results [24]. The
histological results showed 53.4% had CIN1 and 46.6% had
CIN2/3, and cervical cancer in 7.4% women, while in thestudy done by De Vuyst et al CIN1 was seen in 25%
women, CIN 2/3 in 38% women and invasive cancer in 4%
women [24]. In our study the frequency of chronic cervi-
citis with feature of HPV among HIV infected women was
27.4%, this is similar to a study by Mwakigonja et al which
showed a cervicitis in 28%, which was dominated by feature
of Chlamydia trachomatis [15].
The histological results of CIN and invasive cancer seen
in this setting emphasize the importance of introducing a
screening programme for cervical cancer in HIV infected
women. Despite of being at risk of CIN, none of the par-
ticipants in this study had previously been screened for
cervical cancer. This is a major concern in many develop-
ing countries including Tanzania where cervical cancer
screening is largely unavailable, leading to late presenta-
tion with advance cervical cancer [14].
The majority of women acquired HIV infections within
a few years of sexual debut. In this study, an early sexual
debut appeared to be associated with the development of
CIN but was not statistically significant. This concurs with
other studies done in Tanzania whereby an early sexual
debut was not directly associated with CIN [14,17]. In a
study by Matasha et al involving female pupils in
Mwanza, 68% of girls had an early sexual debut [25]. An
earlier age of sexual debut implies a longer period of sex-
ual activity and a higher likelihood of having many sexual
partners [26]. Having multiple sexual partners exposes a
woman to factors predisposing to CIN such as HIV and
STI. This was supported by a study done among Nairobi
prostitutes that showed that women with multiple sexual
partners had an increased risk of developing CIN [27]. A
similar trend was seen in the current study, whereby
women with many sexual partners (more than two) had
more CIN compared to women with few number of sex-
ual partners with significant difference (P< 0.001).
Co-infection with a STI like Chlamydia trachomatis,
herpes simplex or genital warts in the presence of HPV
increased the risk of CIN by causing inflammation which
facilitates HPV persistence and hence cervical lesion and
carcinogenesis [28,29]. In the present study, a previous
history of STI, including genital warts, was associated
with CIN. A previous history of STI was reported to be
a cofactor needed for the progression of HPV infection
to cervical dysplasia and subsequently into cancer. Stud-
ies suggest that HIV induced immunosuppression leads
to inability to control the HPV expression, hence the
persistence of HPV infection and the development of
cervical lesions [30]. This study showed that genital
warts were associated with an increase risk of CIN. A
higher prevalence of HPV infection in Mwanza, found in
the study by Mayaud et al could be a major contributor
to the increased prevalence of genital warts which was
found among HIV infected women in this study. Genital
warts are caused by persistent low risk types of HPV
Table 4 Predictors of CIN on Univariate Logistic Regression
Variables CIN Negative (n=297) CIN Positive (n=58) Crude OR 95% CI p-value
N % N %
History of STI
No 94 (31.6) 2 (3.4) 1
Yes 203 (68.4) 56 (96.6) 13.0 [3.1-54.3] <0.001
Exposure to cigarette smoke
Yes 107 (36.0) 13 (22.4) 1
No 190 (64.0) 45 (77.6) 1.95 [1.01-3.78] 0.048
Ever used contraceptives
Yes 108 (36.4) 21 (36.2) 1
No 189 (63.6) 37 (63.8) 1.01 [0.56-1.81] 0.982
Parity
0 19 (6.4) 5 (8.6) 1
1-2 120 (40.4) 15 (25.9) 0.48 [0.15-1.46] 0.193
3-5 116 (39.1) 33 (56.9) 1.08 [0.37-3.11] 0.885
5+ 42 (14.1) 5 (8.6) 0.45 [0.12-1.75] 0.250
Years since diagnosed HIV +
6 months-1 yr 57 (19.2) 10 (17.2) 1
1-2 years 56 (18.9) 10 (17.2) 1.02 [0.39-2.63] 0.971
More than 2 years 184 (61.9) 38 (65.5) 1.18 [0.55-2.51] 0.673
HAART initiated
No 68 (22.9) 9 (15.5) 1
Yes 229 (77.1) 49 (84.5) 1.62 [0.76-3.46] 0.216
Baseline CD4 Count
Less than 200 cells/mm3 116 (39.1) 34 (58.6) 1
200 cells/mm3 or more 181 (60.9) 24 (41.4) 0.45 [0.25-0.80] 0.007
Current CD4 count
Less than 200 cells/mm3 25 (8.4) 7 (12.1) 1
200 cells/mm3 or more 272 (91.6) 51 (87.9) 0.67 [0.27-1.6] 0.377
Table 5 Predictors of CIN on Multivariate logistic regression
Variables CIN+ (n=58) Adjusted OR 95% CI p-value
N %
No. of live sexual partners
2-5 partners 21 (36.2) 1
5+ partners 37 (63.8) 4.06 [1.86-8.88] <0.001
History of genital warts
No 5 (8.6) 1
Yes 53 (91.4) 16.67 [5.91-47.0] <0.001
History of STI
No 2 (3.4) 1
Yes 56 (96.6) 7.39 [1.67-33.66] 0.010
Baseline CD4 count
200cells/mm3 or more 24 (41.4) 1
Less than 200 cells/mm3 34 (58.6) 2.71 [1.24-5.90] 0.012
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tectable virus still increases the risk of CIN, as shown by
other studies [16,31].
In the current study, women whose baseline CD4 count
was less than 200 cells/mm3 were more likely to have CIN
than those patients with a CD4 count of more than
200cells/mm3. Previous studies have consistently demon-
strated that the amount of CD4 count of less than 200
cells/mm3 is a predictor for having or developing CIN
[14,17]. A study done by Wright et al in New York in 1994
showed that an age of more than 35 years was associated
with a risk of CIN. In the current study, the association be-
tween age and CIN was not statistically significant. The
same conclusion was reached seen in other studies con-
ducted in Kilimanjaro and Dar es Salaam [14,17].
Although we did not find a significant association be-
tween marital status and risk of developing CIN in the
present study, a study done in Kilimanjaro showed that
single women had a tendency to have multiple sexual
partners, a factor which contributed to CIN [17].
Smoking and contraceptive use have been reported to
be established cofactors for HPV progression to cervical
lesion. Carcinogens produced by tobacco are thought to
decrease the immunity in the cervix, thus facilitating
HPV persistence [30]. Furthermore, contraceptive hor-
mones increase the expression of HPV genes in the cer-
vix and facilitate HPV persistence [30]. In the present
study, the association between CIN and those who have
been ever exposed to cigarette and ever used contracep-
tion was not significant. Similarly, there was no difference
in CIN prevalence between Non ART and ART user. This
finding is contrary to a study done by Mwakigonja et al
which noted that the frequency of CIN and invasive can-
cer were higher in women who were non HAART than
those who had been on HAART. Initiation of HAART
has shown to have an impact on reducing the incidence
and progression of CIN [15]. A study by Balandya et al
showed that women who had been on ART for more
than 1 year had more abnormal cervical changes on
VIA compared to those who were on ART for less than
a year. The probable explanation is that despite an in-
creased CD4 count with reconstitution of immunity
there is no clearance of HPV in the cervix [19]. In the
current study, the duration since HIV diagnosis, was
not associated with CIN, which is contrary to a study
done by Kreiss et al which showed that women living
with a HIV infection for more than two years were
more likely to carry high risk HPV infections, which
could result in CIN, compared to women who had been
HIV infected for less than a year [27].
Conclusion
CIN remains a problem among HIV infected women. A
history of multiple sexual partners, a history of genitalwarts, a history STI and a baseline CD4 T lymphocyte of
less than 200cells/mm3 are significant predictors for
CIN. Screening for CIN is recommended for all women
with HIV.
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